智通财经网·2026-02-06 09:59Core Viewpoint - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapies by the National Medical Products Administration, targeting advanced or metastatic pancreatic cancer with KRAS G12D mutation [1] Group 1: Product Development - HRS-4642 is a self-developed KRAS G12D inhibitor in a liposomal formulation [1] - The product is intended for use in combination with gemcitabine and albumin-bound paclitaxel as a first-line treatment [1] - Currently, there are no similar drugs approved for market domestically or internationally [1] Group 2: Market Context - Pancreatic cancer is a common malignant tumor of the digestive system, with 510,566 new cases reported globally in 2022, ranking 12th among malignant tumors [1] - The disease resulted in 467,005 deaths in 2022, making it the 6th leading cause of cancer-related deaths, accounting for approximately 5% of global cancer mortality [1]